非小细胞肺癌脑转移放射治疗进展

doi:10.3760/cma.j.cn113030-20210323-00116

Abstract
Figure/Table
References(38)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract The incidence rate of lung cancer ranks second and the mortality rate ranks first in the world. Non‐small cell lung cancer (NSCLC) is the main pathological type and is prone to brain metastasis. At present, the main treatment methods of brain metastases from NSCLC include surgery, radiotherapy, chemotherapy, molecular targeting and immunotherapy. Radiotherapy is a common local treatment of brain metastases. With the development of technology and drugs, how to combine radiotherapy with other treatments is a hot topic in clinical research. In this article, advances in radiotherapy for brain metastases from NSCLC were reviewed, aiming to provide reference for the selection of treatment options in clinical practice.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zhang Qiaolu
	E Mingyan

Key words： Carcinoma,non‐small cell lung Neoplasms,brain metastasis Radiotherapy

Received: 23 March 2021

Corresponding Authors: E Mingyan, Email: emingyan0996@163.com

Cite this article:

Zhang Qiaolu,E Mingyan. Research progress on the radiotherapy treatment of brain metastases from non‐small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2022, 31(8): 741-744.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20210323-00116 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2022/V31/I8/741

[1] Siegel RL, Miller KD, Jemal A.Cancer statistics, 2017[J]. CA Cancer J Clin, 2017,67(1):7‐30.DOI: 10.3322/caac.21387.
[2] Tsakonas G, De Petris L, Ekman S.Management of brain metastasized non‐small cell lung cancer (NSCLC)‐ From local treatment to new systemic therapies[J]. Cancer Treat Rev, 2017,54:122‐131.DOI: 10.1016/j.ctrv.2017.02.004.
[3] Chang WY, Wu YL, Su PL, et al.The impact of EGFR mutations on the incidence and survival of stagesⅠ to Ⅲ NSCLC patients with subsequent brain metastasis[J]. PLoS One, 2018,13(2):e0192161.DOI: 10.1371/journal.pone.0192161.
[4] Sperduto PW, Yang TJ, Beal K, et al.Estimating survival in patients with lung cancer and brain metastases: an update of the graded prognostic assessment for lung cancer using molecular markers (lung‐molGPA)[J]. JAMA Oncol, 2017,3(6):827‐831.DOI: 10.1001/jamaoncol.2016.3834.
[5] 石远凯,孙燕,于金明,等.中国肺癌脑转移诊治专家共识(2017年版)[J]. 中国肺癌杂志,2017,20(1):1‐13.DOI: 10.3779/j.issn.1009‐3419.2017.01.01.
Shi YK, Sun Y, Yu JM, et al.China experts consensus on the diagnosis and treatment of brain metastases of lung cancer (2017 version)[J]. 2017,20(1):1‐13.DOI: 10.3779/j.issn.1009‐3419.2017.01.01.
[6] Mulvenna P, Nankivell M, Barton R, et al.Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non‐small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non‐inferiority, randomised trial[J]. Lancet, 2016,388(10055):2004‐2014.DOI: 10.1016/S0140‐6736(16)30825‐X.
[7] Aoyama H, Tago M, Shirato H.Stereotactic radiosurgery with or without whole‐brain radiotherapy for brain metastases: secondary analysis of the JROSG 99‐1 randomized clinical trial[J]. JAMA Oncol, 2015,1(4):457‐464.DOI: 10.1001/jamaoncol.2015.1145.
[8] Kim KH, Cho BC, Lee CG, et al.Hippocampus‐sparing whole‐brain radiotherapy and simultaneous integrated boost for multiple brain metastases from lung adenocarcinoma: early response and dosimetric evaluation[J]. Technol Cancer Res Treat, 2016,15(1):122‐129.DOI: 10.1177/1533034614566993.
[9] Gondi V, Pugh SL, Tome WA, et al.Preservation of memory with conformal avoidance of the hippocampal neural stem‐cell compartment during whole‐brain radiotherapy for brain metastases (RTOG0933): a phase II multi‐institutional trial[J]. J Clin Oncol, 2014,32(34):3810‐3816.DOI: 10.1200/JCO.2014.57.2909.
[10] Yamamoto M, Serizawa T, Shuto T, et al.Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi‐institutional prospective observational study[J]. Lancet Oncol, 2014,15(4):387‐395.DOI: 10.1016/S1470‐2045(14)70061‐0.
[11] Sperduto PW, Shanley R, Luo X, et al.Secondary analysis of RTOG9508, a phase 3 randomized trial of whole‐brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1‐3 brain metastases; poststratified by the graded prognostic assessment (GPA)[J]. Int J Radiat Oncol Biol Phys, 2014,90(3):526‐531.DOI: 10.1016/j.ijrobp.2014.07.002.
[12] Brown PD, Jaeckle K, Ballman KV, et al.Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial[J]. JAMA, 2016,316(4):401‐409.DOI: 10.1001/jama.2016.9839.
[13] Li N, Zeng ZF, Wang SY, et al.Randomized phase Ⅲ trial of prophylactic cranial irradiation versus observation in patients with fully resected stage ⅢA‐N2 nonsmall‐cell lung cancer and high risk of cerebral metastases after adjuvant chemotherapy[J]. Ann Oncol, 2015,26(3):504‐509.DOI: 10.1093/annonc/mdu567.
[14] De Ruysscher D, Dingemans A C, Praag J, et al.Prophylactic cranial irradiation versus observation in radically treated stage Ⅲ non‐small‐cell lung cancer: a randomized phase Ⅲ NVALT‐11/DLCRG‐02 Study[J]. J Clin Oncol, 2018,36(23):2366‐2377.DOI: 10.1200/JCO.2017.77.5817.
[15] Loganadane G, Hendriks L, Le Péchoux C, et al.The current role of whole brain radiation therapy in non‐small cell lung cancer patients[J]. J Thorac Oncol, 2017,12(10):1467‐1477.DOI: 10.1016/j.jtho.2017.07.006.
[16] Bearz A, Garassino I, Tiseo M, et al.Activity of pemetrexed on brain metastases from non‐small cell lung cancer[J]. Lung Cancer, 2010,68(2):264‐268.DOI: 10.1016/j.lungcan.2009.06.018.
[17] Barlesi F, Gervais R, Lena H, et al.Pemetrexed and cisplatin as first‐line chemotherapy for advanced non‐small‐cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07‐01)[J]. Ann Oncol, 2011,22(11):2466‐2470.DOI: 10.1093/annonc/mdr003.
[18] Addeo R, De Rosa C, Faiola V, et al.Phase 2 trial of temozolomide using protracted low‐dose and whole‐brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases[J]. Cancer, 2008,113(9):2524‐2531.DOI: 10.1002/cncr.23859.
[19] Koutras AK, Marangos M, Kourelis T, et al.Surgical management of cerebral metastases from non‐small cell lung cancer[J]. Tumori, 2003,89(3):292‐297.
[20] Shen Z, Jiang Z, Ye D, et al.Growth inhibitory effects of DJ‐1‐small interfering RNA on laryngeal carcinoma Hep‐2 cells[J]. Med Oncol, 2011,28(2):601‐607.DOI: 10.1007/s12032‐010‐9474‐7.
[21] Hartford AC, Paravati AJ, Spire WJ, et al.Postoperative stereotactic radiosurgery without whole‐brain radiation therapy for brain metastases: potential role of preoperative tumor size[J]. Int J Radiat Oncol Biol Phys, 2013,85(3):650‐655.DOI: 10.1016/j.ijrobp.2012.05.027.
[22] Mahajan A, Ahmed S, McAleer MF, et al.Post‐operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single‐centre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2017,18(8):1040‐1048.DOI: 10.1016/S1470‐2045(17)30414‐X.
[23] Singhi EK, Horn L, Sequist LV, et al.Advanced non‐small cell lung cancer: sequencing agents in the EGFR‐mutated/ALK‐rearranged populations[J]. Am Soc Clin Oncol Educ Book, 2019,39:e187‐e197.DOI: 10.1200/EDBK_237821.
[24] Du XJ, Pan SM, Lai SZ, et al.Upfront cranial radiotherapy vs.egfr tyrosine kinase inhibitors alone for the treatment of brain metastases from non‐small‐cell lung cancer: a meta‐analysis of 1465 patients[J]. Front Oncol, 2018,8:603.DOI: 10.3389/fonc.2018.00603.
[25] Magnuson WJ, Yeung JT, Guillod PD, et al.Impact of deferring radiation therapy in patients with epidermal growth factor receptor‐mutant non‐small cell lung cancer who develop brain metastases[J]. Int J Radiat Oncol Biol Phys, 2016,95(2):673‐679.DOI: 10.1016/j.ijrobp.2016.01.037.
[26] Chen H, Wu A, Tao H, et al.Concurrent versus sequential whole brain radiotherapy and TKI in EGFR‐mutated NSCLC patients with brain metastasis: a single institution retrospective analysis[J]. Medicine (Baltimore), 2018,97(44):e13014.DOI: 10.1097/MD.0000000000013014.
[27] Jiang T, Su C, Li X, et al.EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases[J]. J Thorac Oncol, 2016,11(10):1718‐1728.DOI: 10.1016/j.jtho.2016.05.013.
[28] Miyawaki E, Kenmotsu H, Mori K, et al.Optimal sequence of local and EGFR‐TKI therapy for EGFR‐mutant non‐small cell lung cancer with brain metastases stratified by number of brain metastases[J]. Int J Radiat Oncol Biol Phys, 2019,104(3):604‐613.DOI: 10.1016/j.ijrobp.2019.02.051.
[29] Yang WC, Xiao F, Shih JY, et al.Epidermal growth factor receptor mutation predicts favorable outcomes in non‐small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery[J]. Radiother Oncol, 2018,126(2):368‐374.DOI: 10.1016/j.radonc.2017.10.010.
[30] Magnuson WJ, Lester‐Coll NH, Wu AJ, et al.Management of brain metastases in tyrosine kinase inhibitor‐naïve epidermal growth factor receptor‐mutant non‐small‐cell lung cancer: a retrospective multi‐institutional analysis[J]. J Clin Oncol, 2017,35(10):1070‐1077.DOI: 10.1200/JCO.2016.69.7144.
[31] 周燕,欧阳雯,余静,等.脑部放疗的选择对驱动基因阳性非小细胞肺癌脑转移患者生存的影响[J]. 中华放射医学与防护杂志, 2020,40(05):359‐364.DOI: 10.3760/cma.j.issn.1004‐4221.2012.04.00.
Zhou Y, Ouyang W, Yu J, et al.Involved‐field radiotherapy versus elective nodal irradiation in combination with concurrent chemotherapy for locally advanced non‐small cell lung cancer: A prospective ran domized clinical stud[J]. Chin J Radiat Oncol, 2020,40(05):359‐364.DOI: 10.3760/cma.j.issn.1004‐4221.2012.04.00.
[32] Camidge D R, Dziadziuszko R, Peters S, et al.Updated efficacy and safety data and impact of the EML4‐ALK fusion variant on the efficacy of alectinib in untreated ALK‐positive advanced non‐small cell lung cancer in the global phase Ⅲ ALEX study[J]. J Thorac Oncol, 2019,14(7):1233‐1243.DOI: 10.1016/j.jtho.2019.03.007
[33] Johung KL, Yeh N, Desai NB, et al.Extended survival and prognostic factors for patients with ALK‐rearranged non‐small‐cell lung cancer and brain metastasis[J]. J Clin Oncol, 2016,34(2):123‐129.DOI: 10.1200/JCO.2015.62.0138.
[34] Garon EB, Hellmann MD, Rizvi NA, et al.Five‐year overall survival for patients with advanced non‒small‐cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE‐001 study[J]. J Clin Oncol, 2019,37(28):2518‐2527.DOI: 10.1200/JCO.19.00934.
[35] D'Souza NM, Fang P, Logan J, et al.Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies[J]. Front Oncol, 2016,6:212.DOI: 10.3389/fonc.2016.00212.
[36] Chen L, Douglass J, Kleinberg L, et al.Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non‐small cell lung cancer, melanoma,renal cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2018,100(4):916‐925.DOI: 10.1016/j.ijrobp.2017.11.041.
[37] Shepard MJ, Xu Z, Donahue J, et al.Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non‐small cell lung cancer to the brain: a matched cohort study[J]. J Neurosurg, 2019:1‐8.DOI: 10.3171/2019.4.JNS19822.
[38] Martin AM, Cagney DN, Catalano PJ, et al.Immunotherapy and symptomatic radiation necrosis in patients with brain metastases treated with stereotactic radiation[J]. JAMA Oncol, 2018,4(8):1123‐1124.DOI: 10.1001/jamaoncol.2017.3993.